← Back to Search

Automatic Self Transcending Meditation for Depression

N/A
Waitlist Available
Led By Monali Malvankar, PhD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first office visit, week 0, 4, 6, 8, 12, and 24
Awards & highlights

Study Summary

Patients with dry eye disease (DED) will be randomized to Automatic Self Transcending Meditation (ASTM) plus Treatment as Usual (TAU) or TAU alone to assess changes in Health-related quality of life (HRQoL). HRQoL is a vital construct focusing on impact of health on quality of life. HRQoL data is used in economic evaluations, a component of health economics that compares the cost and consequences of alternative courses of action. This helps policy-makers make complex financial decisions. Along with HRQoL we will measure changes in extent of depression as well as anxiety. Previously published data lacks information of HRQoL in patients with DED. Through this study we shall attempt to correlate HRQoL in this population and assess if ASTM confers changes in HRQoL along with depressive and anxiety symptoms.

Eligible Conditions
  • Depression
  • Quality of Life
  • Eye Diseases
  • Anxiety

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first office visit, week 0, 4, 6, 8, 12, and 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and first office visit, week 0, 4, 6, 8, 12, and 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Health-related quality of life (HRQoL)
Secondary outcome measures
Anxiety
Depression
Dry Eye Assesment
+1 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Automatic Self Transcending MeditationActive Control1 Intervention
Automatic Self Transcending Meditation (ASTM) may help with depression, anxiety, stress, PTSD, and may have a positive impact on quality of life of participants diagnosed with dry eye disease. ASTM is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.
Group II: Treatment as Usual (TAU)Placebo Group1 Intervention
Participants continue to receive treatment as usual including dry eye disease medications.

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
659 Previous Clinical Trials
413,476 Total Patients Enrolled
27 Trials studying Depression
190,084 Patients Enrolled for Depression
Monali Malvankar, PhDPrincipal InvestigatorWestern University, Canada
1 Previous Clinical Trials
142 Total Patients Enrolled
1 Trials studying Depression
142 Patients Enrolled for Depression

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Automatic Self Transcending Meditation (ASTM) in Patients With Dry Eye Disease
Monali Malvankar 2018. "Automatic Self Transcending Meditation (ASTM) in Patients With Dry Eye Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03087006.
All > Dry Eye
~37 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top